Clinical Significance of Procalcitonin, C-Reactive Protein, and Interleukin-6 in Helping Guide the Antibiotic Use for Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Table 1
Demographic features and laboratory findings of the patients.
sCOPD
AECOPD
value
Male
22
47.8
200
61.5
0.076
Age (age)
0.522
Length of stay (days)
0.117
In intensive care
0
35
10.8
<0.001
Symptom
Cough
38
82.6
321
98.8
<0.001
Expectoration
35
76.1
320
98.5
<0.001
Shortness of breath
12
26.1
113
34.8
0.244
Wheezes
11
23.9
88
27.1
0.679
Chest tightness
20
43.5
121
37.2
0.406
Fever
7
15.2
85
26.2
0.108
Chest pain
2
4.4
23
7.1
0.706
Dyspnea
0
24
7.4
0.113
Purulent sputum
5
10.9
110
33.9
<0.001
Diabetes
14
30.4
65
20
0.106
Coronary heart disease
9
19.6
101
31.1
0.11
Hypertension
28
60.9
187
57.6
0.551
Cerebral infarction
9
19.6
63
19.4
0.977
Bronchodilation
4
8.7
41
12.6
0.446
Bronchial asthma
16
34.8
72
22.2
0.059
Pulmonary embolism
0
16
4.9
0.25
Malignant tumor
0
9
2.8
0.528
PCT (ng/mL)
0.005
CRP (mg/mL)
<0.001
IL-6 (pg/mL)
<0.001
Lung CT indicated infection
14
30.4
223
68.6
<0.001
Abnormal pulmonary auscultation
12
26.1
249
76.6
<0.001
Antibiotic used
12
26.1
264
81.2
<0.001
Course of use of the first antibiotic (days)
0.24
The total course of antibiotics (days)
0.52
Changed antibiotics
0
61
18.8
0.001
Antibiotic step-down therapy
1
2.2
35
10.8
0.115
Combined other anti-gram-negative bacilli antibacterial drugs
0
3
0.9
0.822
Combined other anti-gram-positive cocci antibacterial drugs
